Publications by authors named "W Bernhardt"
Article Synopsis
- The German Lipoprotein Apheresis Registry (GLAR) began in 2012 and collected data from 2,301 patients undergoing lipoprotein apheresis (LA) for high cholesterol and lipoprotein(a) levels over 11 years.
- The data showed significant reductions in LDL-C (68.8%) and Lp(a) (72.9%) immediately after LA treatment, with substantial decreases in major coronary events (MACE) over the treatment period, particularly an 85% reduction in patients with high Lp(a) levels.
- Adverse events related to LA were low (around 5%) mainly involving minor issues like puncture problems, with no severe side effects leading to treatment termination.
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) is caused by mutations in one of at least five genes and leads to kidney failure usually in mid adulthood. Throughout the literature, variable numbers of families have been reported, where no mutation can be found and therefore termed ADTKD-not otherwise specified. Here, we aim to clarify the genetic cause of their diseases in our ADTKD registry.
View Article and Find Full Text PDFKidney injury significantly increases overall mortality. Neutrophilic granulocytes (neutrophils) are the most abundant human blood leukocytes. They are characterized by a high turnover rate, chiefly controlled by granulocyte colony stimulating factor (G-CSF).
View Article and Find Full Text PDFIntroduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid-lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (LA). Data are scarce on patients who, after escalation of LLT with PCSK9 antibodies, have commenced chronic LA or PCSK9 antibody treatment during ongoing long-term LA.
Patients And Methods: In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutively identified.